title stringlengths 1 1.19k | keywords stringlengths 0 668 | concept stringlengths 0 909 | paragraph stringlengths 0 61.8k | PMID stringlengths 10 11 |
|---|---|---|---|---|
3.1. Safety | nausea, vomiting, anemia, abdominal pain | ADVERSE EVENTS, ADVERSE EVENT, ADVERSE EVENT, ANEMIA | Most of the study patients received 8 or more doses of nimotuzumab and at least 2 cycles of chemotherapy. Adverse events were reported in 49 patients (73.11%). A total of 319 adverse events of 83 different types were recorded. Treatment-related adverse events were recorded in 8.1% of patients. Severe AEs related to the... | PMC10162878 |
3.2. Survival Analysis | DISEASE, METASTATIC DISEASE | In the front-line setting, median overall survival of 9.0 months (95% CI; 8.36-15.11) was reached, and 1- and 2-year survival rates reached values of 38.8 and 7.6, respectively, while the overall mPFS was 8.03 ± 0.99 (6.08-9.90) months.In patients with locally advanced disease, a global median OS of 16.36 months (95% C... | PMC10162878 | |
3.3. Clinical Response | DISEASE, REMISSION, METASTATIC DISEASE, RECURRENT DISEASE | The study obtained a 3.1% of complete remission and 15.4% of partial remission, which contributed to an objective response rate of 18.5%, and the disease control rate was achieved in 43.1% of the study patients (In patients who received 8 or more doses of nimotuzumab, the objective response increased to 26.1% and the d... | PMC10162878 | |
4. Discussion | tumor, neutropenia, neuropathy, toxicity, thrombocytopenia, rash, pancreatic cancer, unresectable pancreatic cancer, tumors, pancreatic adenocarcinoma | ADVERSE REACTIONS, TUMOR, NEUTROPENIA, FOLLICULITIS, METASTATIC PANCREATIC CANCER, ADVERSE EVENTS, NEUROPATHY, THROMBOCYTOPENIA, DISEASE, METASTATIC DISEASE, PANCREATIC CANCER, INFILTRATING, TUMORS, PANCREATIC ADENOCARCINOMA, INFILTRATED | In the present study, with a mean follow-up time of 11.4 months, the very low toxicity profile of nimotuzumab was confirmed when administered in combination with gemcitabine in conditions of real-world practice.The fundamental problem in terms of toxicity of the therapies that target the EGFR is the appearance of sever... | PMC10162878 |
5. Conclusions | PDAC | Nimotuzumab combined with gemcitabine as first-line treatment option represents a safe and useful alternative for the treatment of PDAC under real-world conditions. The administration of nimotuzumab as part of possible multimodal combination of agents that target a subset of cancer-associated fibroblasts or their secre... | PMC10162878 | |
Acknowledgments | Carvajal | The authors thank Rider Isaac Verdecia, Bachelor in English Language, Associate Professor, and Master in Higher Education Communicative Competence, who help with the language edition. Also, the authors would like to acknowledge the Cuban Network of Clinical Research Coordinators (Yusleidy Blanco González, Mileydis Soto... | PMC10162878 | |
Data Availability | The data sets used and/or analyzed during the current study are available from the corresponding author upon reasonable request. | PMC10162878 | ||
Conflicts of Interest | Three authors currently work at the Center of Molecular Immunology, the institution that generated and originally patented nimotuzumab. The other authors do not have any commercial or financial relationships that could be taken as a potential conflict of interest. | PMC10162878 | ||
Authors' Contributions | B. Martorell, P. | ADVERSE EVENTS, DISEASE, ADENOCARCINOMA OF THE PANCREAS | Study concepts and design were carried out by Y. Sánchez, Y. Saumell, A. R. Valls, and P. P. Guerra. Literature research was carried out by Y. Sánchez, Y. Saumell, A. R. Valls, and P. P. Guerra. Clinical data collection was carried out by Y. Sánchez, M. L. Concepción, Y. Amador, A. Piriz, R. Rabassa, A. Leyva, O. Argue... | PMC10162878 |
Background | anhedonia | CHRONIC PAIN | Neuropsychopharmacologic effects of long-term opioid therapy (LTOT) in the context of chronic pain may result in subjective anhedonia coupled with decreased attention to natural rewards. Yet, there are no known efficacious treatments for anhedonia and reward deficits associated with chronic opioid use. Mindfulness-Orie... | PMC10106294 |
Methods | Veterans receiving LTOT ( | PMC10106294 | ||
Results | anhedonia | Patients treated with MORE demonstrated significantly increased LPP and SCL to natural reward cues and greater decreases in subjective anhedonia relative to those in the SG. The effect of MORE on reducing anhedonia was statistically mediated by increases in LPP response during savoring. | PMC10106294 | |
Conclusions | chronic pain, anhedonia | DISORDER, CHRONIC PAIN | MORE enhances motivated attention to natural reward cues among chronic pain patients on LTOT, as evidenced by increased electrocortical and sympathetic nervous system responses. Given neurophysiological evidence of clinical target engagement, MORE may be an efficacious treatment for anhedonia among chronic opioid users... | PMC10106294 |
Key words | PMC10106294 | |||
Materials and methods | PMC10106294 | |||
Participants | chronic pain | CHRONIC PAIN | In this ancillary mechanistic study, we added a neurophysiological assessment protocol to an ongoing clinical trial (NCT02935621) where EEG outcomes were not proposed as part of the original clinical trial design. This mechanistic study evaluated neurophysiological (EEG and SCL) data from a sample of Veterans with chro... | PMC10106294 |
Procedures | Following screening, participants who gave written informed consent completed demographic and clinical assessments, including the Snaith Hamilton Anhedonia and Pleasure Scale (SHAPS) (Snaith et al., | PMC10106294 | ||
Interventions | pain | EVENTS, CHRONIC PAIN | The manualized MORE intervention program provided training in mindfulness, reappraisal, and savoring skills as techniques to cope with opioid craving, pain, and negative affect. Group sessions were 2 h long and led by a psychologist. Sessions included training in mindful breathing and body scan techniques to help patie... | PMC10106294 |
Assessment of natural reward responsiveness | In an experimental laboratory session, participants were presented with images representing natural rewards or neutral cues. On each trial, participants were first shown a fixation cross for 500 ms, followed by 250–500 ms jittered blank screen and then an image and instruction label for 5000 ms. Across 64 trials, cues ... | PMC10106294 | ||
EEG | BRAIN | EEG was continuously recorded from 10 midline scalp sites (Fz, F3, F4, FC1, FC2, FCz, Cz, CP1, CP2, PZ) using an active sensor cap with Ag/AgCl electrodes (actiCap GmbH, Herrsching, Germany). All recordings were collected by an actiCHamp amplifier (Brain Products GmbH, Gilching, Germany). Data were acquired at a sampli... | PMC10106294 | |
Skin conductance | SKIN | Skin conductance sensors were placed on the middle phalanx of the index and middle fingers of the non-dominant hand. A BIOPAC MP160 amplifier provided a constant voltage (0.5 V) across the two electrodes. Change relative to a 500 ms pre-stimulus baseline was computed in half-second epochs. | PMC10106294 | |
Anhedonia | The SHAPS (Snaith et al., | PMC10106294 | ||
Positive affect | POSITIVE | The Positive and Negative Affect Schedule-short form (PANAS-SF) was used to assess positive affect with 10 items rated on a Likert-type scale (1 = | PMC10106294 | |
Reward experience | One item from the Applied Mindfulness Process Scale (AMPS; Li, Black, & Garland, | PMC10106294 | ||
Statistical analysis | anhedonia | This mechanistic study was powered to detect the effects of MORE on neurophysiological processes. Power analysis conducted with G*power 3.1 indicated that 60 subjects were required to detect a statistically significant (Given the canonical time window of the LPP and our Next, to perform an intention-to-treat analysis o... | PMC10106294 | |
Results | PMC10106294 | |||
Baseline equivalence | There was no significant between-groups difference by Treatment condition on the LPP ( | PMC10106294 | ||
Treatment effects on LPP response | Effects of treatment on the LPP (Changes in parietal (Pz) late positive potential (LPP) during (Difference waves (post-treatment minus pre-treatment) depicting effects of Mindfulness-Oriented Recovery Enhancement (MORE) | PMC10106294 | ||
Treatment effects on SCL response | Effects of treatment on SCL (Difference waves (post-treatment minus pre-treatment) depicting effects of Mindfulness-Oriented Recovery Enhancement (MORE) | PMC10106294 | ||
Treatment effects on anhedonia, positive affect, and reward experience | In LMM of SHAPS scores, the Treatment × Time interaction was significant, With regard to PANAS positive affect, although the main effect of Time was significant | PMC10106294 | ||
Association between neurophysiological mechanisms and anhedonia, positive affect, and reward experience | Across the entire sample, pre-post increases in LPP during the regulate strategy correlated with lower SHAPS scores throughout the follow-up, Path model indicating that the effect of Mindfulness-Oriented Recovery Enhancement (MORE) | PMC10106294 | ||
Discussion | anhedonia, OUD, chronic pain, decreased anhedonia, depression | CHRONIC PAIN, BRADLEY, SKIN | Here we obtained neurophysiological evidence in support of the hypothesis that MORE increases motivated attention to natural reward cues in chronic pain patients on LTOT – effects that were associated with decreased anhedonia. Relative to an active SG psychotherapy control condition, participants in the MORE group exhi... | PMC10106294 |
Supplementary material | For supplementary material accompanying this paper visit https://doi.org/10.1017/S0033291721003834.click here to view supplementary material | PMC10106294 | ||
Author contributions | SPENCER | Eric L. Garland: conceptualization, methodology, formal analysis, funding acquisition, project administration, investigation, resources, data curation, writing – original and editing. Spencer Fix: software, methodology, formal analysis, data curation, writing-original and editing, visualization, investigation. Justin H... | PMC10106294 | |
Financial support | ABUSE | This work was supported by W81XWH-16-1-0522 from the Department of Defense (PI: Garland), R01DA042033 from the National Institute on Drug Abuse (PI: Garland), and R61AT009296 from the National Center for Complementary and Integrative Health (PI: Garland). The content is solely the responsibility of the authors and does... | PMC10106294 | |
Conflict of interest | Eric Garland, Ph.D., LCSW is the Director of the Center on Mindfulness and Integrative Health Intervention Development. The Center provides Mindfulness-Oriented Recovery Enhancement (MORE), mindfulness-based therapy, and cognitive behavioral therapy in the context of research trials for no cost to research participants... | PMC10106294 | ||
References | PMC10106294 | |||
1. Introduction | obesity, OA, osteoarthritis, pain, ColEx, disability, musculoskeletal problems, knee pain, osteoarthritic, injuries | OBESITY, DEGENERATION, OSTEOARTHRITIS, ARTHRITIC CHANGES, OSTEOARTHRITIS, DISEASE | Athletic injuries are commonly implicated in the development of early osteoarthritic (EOA) changes in the knee. These changes have a significant impact on athletic performance, and therefore the early detection of EOA is paramount. The objective of the study is to assess the impact of different interventions on individ... | PMC10706409 |
2. Methods | PMC10706409 | |||
2.1. Design and Participants | knee injury, pain, knee muscle strength and knee muscle, knee pain, trauma | HAND OSTEOARTHRITIS, SECONDARY | A double-blind, quasi-randomized trial was conducted in the hospital settings of Kasturba Medical college, Mangalore, between March 2021 and March 2022. The primary outcomes were measured using the pain scale and assessed using the visual analogue scale (VAS). The functional outcomes were measured using the knee injury... | PMC10706409 |
2.2. Instruments | A handheld dynamometer was used to assess the muscle strength, ROM was assessed using the universal goniometer, and the KOOS scale was used to evaluate the patient-reported outcomes. | PMC10706409 | ||
2.3. Intervention | abductors, hip muscle | Group 1—exercise therapy group;Group 2—collagen supplementation;Group 3—combined intervention of exercise therapy and collagen supplementation.The exercises prescribed to both groups were:hip muscle strengthening exercises, including hip flexors, abductors, adductors, and extensors;knee muscle strengthening exercises, ... | PMC10706409 | |
2.4. Data Collection | musculoskeletal injury, knee injury | HAND OSTEOARTHRITIS | The study received ethical approval from the Institutional Ethics Committee, KMC Mangalore, Manipal Academy of Higher Education (IECKMC MLR 02-2021/54). The study was enrolled into India’s clinical trial registry under the identifier CTRI/2021/04/033091. Recreational athletes of either gender, aged from 18 to 52 years,... | PMC10706409 |
2.5. Statistical Analysis | The collected data were entered into the Statistical Package for Social Sciences (SPSS) version 21.0. A descriptive analysis of the baseline characteristics of the study subjects was carried out. Baseline data were compared between groups, and as the data were normally distributed, an unpaired | PMC10706409 | ||
3. Results | PMC10706409 | |||
3.1. Patient Demographics | ColEx | Patient demographics: The study included 48 participants with a mean age of approximately 29–30 years, divided into three groups: collagen + exercise (ColEx), collagen (Col), and exercise (Ex). | PMC10706409 | |
3.2. Pain Score at Weeks 4, 8 and 12 | Pain | Pain score: Pain levels significantly reduced in all three groups over 12 weeks (At rest, ColEx: | PMC10706409 | |
3.3. Knee Flexion ROM at Weeks 4, 8 and 12 | knee flexion ROM | The knee flexion ROM ( | PMC10706409 | |
3.4. Knee Flexor Strength at Weeks 4, 8 and 12 | The knee flexor strength at baseline was statistically significant in all three groups from baseline to 12 weeks ( | PMC10706409 | ||
3.5. KOOS Score at Weeks 4, 8 and 12 | ColEx, pain | KOOS Score: (All three groups exhibited significant reductions in pain levels over the 12-week study period. The ColEx group experienced a substantial reduction in pain at rest, with a | PMC10706409 | |
4. Discussion | muscle weakness, functional disability, pain, reduced pain, trauma | DISEASE PROGRESSION, MUSCLE WEAKNESS, EVENTS | The objective of this study was to determine the efficacy, superiority, and relative benefits of three different paradigms of treatment, i.e., exercise therapy, collagen supplementation, and a combination of collage supplementation with exercise therapy, in alleviating pain, and improving muscle strength, range of moti... | PMC10706409 |
5. Conclusions and Future Directions | OA | DISEASE PROGRESSION | The influence of sports practice on the development of EOA is a cause for concern. The ability to treat OA in its early stages may be largely linked to alterations in specific extrinsic or intrinsic factors associated with the patient to spare the joint from further disease progression; these factors include sports pra... | PMC10706409 |
Author Contributions | A.J.P. and C.E.—conceptualization of the topics. D.T.T.—data collection and writing of the manuscript. S.R. and M.C.D.—reviewing of the manuscript. Y.D.K., V.D.P., V.P.—final manuscript editing and supervision of the study. All authors have read and agreed to the published version of the manuscript. | PMC10706409 | ||
Institutional Review Board Statement | The study received ethical approval from the Institutional Ethics Committee, KMC Mangalore, Manipal Academy of Higher Education (IECKMC MLR 02-2021/54). | PMC10706409 | ||
Informed Consent Statement | Informed consent was obtained from all subjects involved in the study. | PMC10706409 | ||
Data Availability Statement | Available on OSF–DOI 10.17605/OSF.IO/V6Y9P. | PMC10706409 | ||
Conflicts of Interest | The authors declare no competing conflict of interest. | PMC10706409 | ||
References | knee flexion ROM, pain, ColEx, extensors, knee flexion | RECRUITMENT | Patient recruitment and study design flowchart. * collagen + exercise ** collagen *** exercise.Changes in the range of motion (ROM) of knee flexion among the three treatment groups (collagen + exercise—ColEx, collagen—Col, and exercise—Ex) at different time intervals (4 weeks, 8 weeks, and 12 weeks) during the study pe... | PMC10706409 |
Background | EXPOSURE TO ALCOHOL | Exposure to alcohol advertising and sponsorship through elite sport is associated with harmful use of alcohol. Owing to strong financial and cultural ties between alcohol and sport in Australia, policy action to restrict alcohol sport sponsorship is unlikely to occur without strong public support for change. This study... | PMC9969365 | |
Methods | A sample of 1,075 Australian adults aged 18–49 years who planned to watch an National Rugby League (NRL) State of Origin series game, featuring prominent alcohol sponsorship, was recruited through an online panel and randomly assigned to one of three conditions: control (neutral advertisement); counter-advertisement ex... | PMC9969365 | ||
Results | sports-related alcohol | Compared to both the control advertisement and the counter-advertisement exposing alcohol harms, participants who viewed the counter-advertisement exposing alcohol sponsorship and harms were significantly more likely to indicate support for each of four policies aimed at restricting sports-related alcohol marketing, in... | PMC9969365 | |
Conclusion | Counter-advertising employing messages that expose and critique the intent and impact of pervasive alcohol sponsorship in sport has potential to bolster public support for policies targeting alcohol sport sponsorship, diminish beliefs supportive of alcohol industry marketing strategies and enhance negative views of alc... | PMC9969365 | ||
Supplementary Information | The online version contains supplementary material available at 10.1186/s12889-023-15250-5. | PMC9969365 | ||
Keywords | PMC9969365 | |||
Background | sports-related alcohol | EVENTS, EVENT, HOLIDAYS | Alcohol companies invest heavily in sponsorship of elite sport, with 30 of the leading alcoholic beverage brands globally spending a combined $764.5 million on sport sponsorship in 2018 [While spectator participation levels at sporting events have been impacted by the COVID-19 pandemic, around one in five Australians a... | PMC9969365 |
Method | PMC9969365 | |||
Design and participants | sports-related alcohol | EVENT | The study design was a pre-post, between-subjects experiment comprising three counter-advertising conditions: (A) control (neutral ad); (B) counter-ad exposing alcohol harms; (C) counter-ad exposing alcohol sponsorship and harms. A sample of Australian adults was recruited by Ipsos from their non-probability online pan... | PMC9969365 |
Counter-advertising intervention | The counter-ad The counter-ad The | PMC9969365 | ||
Measures | The set of outcomes that form the basis of this paper are described below. Other domains measured in the baseline and/or follow-up surveys (e.g., brand awareness; sponsorship recall and recognition; image-based similarity; event-sponsor fit; brand attitudes, preferences and purchase intentions; alcohol harm beliefs; al... | PMC9969365 | ||
Responses to counter-advertisement | confusion | Immediately following counter-ad exposure at baseline, participants rated their cognitive (e.g., believability, relevance to them), motivational (i.e., felt motivated to reduce the amount of alcohol I drink) and emotional (e.g., confusion, surprise) responses to their assigned counter-ad using questions adapted from pr... | PMC9969365 | |
Policy support | sports-related alcohol, neutral/oppose’ | At follow-up, participants indicated their level of support (1 = ‘strongly oppose’ to 7 = ‘strongly support’) for four proposed policies aimed at restricting sports-related alcohol marketing. Responses were collapsed into ‘support’ (5–7) and ‘neutral/oppose’ (1–4) categories. | PMC9969365 | |
Beliefs about the alcohol industry | ’ | At follow-up, participants indicated the extent to which they agreed or disagreed (1 = ‘strongly disagree’ to 7 = ‘strongly agree’) with three positively framed and two negatively framed statements about alcohol companies. Responses were collapsed into ‘agree’ (5–7) or ‘neutral/disagree’ (1–4) categories. Participants... | PMC9969365 | |
Baseline characteristics | Participants recorded their gender, age, residential postcode, highest level of educational attainment, parental status and frequency of drinking alcohol over the last 12 months. Socio-economic status (SES) was determined according to the Australian Bureau of Statistic’s Index of Relative Socio-Economic Disadvantage ra... | PMC9969365 | ||
Statistical analysis | ’ cognitive, motivational and emotional responses | SENSITIVITY, REGRESSIONS | Data were analysed using Stata/MP V.16.1 (StataCorp, College Station, Texas). One-way analyses of variance with Bonferroni-adjusted post hoc pairwise comparisons were used to test for differences in participants’ cognitive, motivational and emotional responses to the counter-ad (measured at baseline) by condition. Over... | PMC9969365 |
Results | PMC9969365 | |||
Sample characteristics | The final sample comprised n = 1,075 eligible adults who were recruited and completed data collection (baseline survey, short exposure tasks, follow-up survey) between 2 June and 18 July 2021 (see Fig.
Sample characteristics by counter-advertising condition (n = 1075)Notes: Percentages are rounded so may not sum to 10... | PMC9969365 | ||
Responses to counter-advertisement at baseline | As shown in Table
Participants’ cognitive, motivational and emotional responses to counter-advertisement at baseline (n = 1075)oxy_comment_start comment="The footnotes have gotten mixed up in your reordering of the tables. Thus, we have fixed these to match how the tables are currently being shown in the proof. Howeve... | PMC9969365 | ||
Policy support at follow-up | REGRESSION | Across all conditions, participants showed stronger support for a ban on alcohol during sporting broadcasts at times when children watch TV (63%) than a ban on alcohol advertising at sports grounds (47%; McNemar’s χ
Effects of counter-advertising condition on policy support and beliefs about alcohol industry marketing ... | PMC9969365 | |
Beliefs about the alcohol industry at follow-up | As shown in Table | PMC9969365 | ||
Discussion | cancer, sports-related alcohol, SD, Cancer | CANCER, SECONDARY, EVENT, CANCER | Findings from the present study indicate that counter-advertising exposing alcohol sponsorship and harms has potential to bolster public support for policies to restrict sports-related alcohol marketing, diminish beliefs supportive of alcohol industry marketing and enhance negative views of alcohol companies and their ... | PMC9969365 |
Conclusion | These study findings suggest that counter-advertising exposing industry marketing of harmful products offers a promising avenue for increasing public support for regulatory change in relation to alcohol sponsorship of elite sport and shifting beliefs about the alcohol industry and the acceptability of its marketing pra... | PMC9969365 | ||
Acknowledgements | The authors thank the advertising agency, | PMC9969365 | ||
Author Contribution | HD, MS and MW designed the experiment. MS oversaw data collection and conducted data analysis in consultation with HD. MS and HD wrote the initial draft of the paper. All authors were involved in refining study protocols, interpretation of data, critically revising the paper and approving the final version. | PMC9969365 | ||
Funding | This research was funded by an Australian National Health and Medical Research Council Project Grant (GNT1159262). | PMC9969365 | ||
Data Availability | The data used and analysed in the current study are available from the corresponding author on reasonable request. | PMC9969365 | ||
Declarations | PMC9969365 | |||
Ethical approval and consent to participate | Cancer | CANCER | Ethical approval to conduct the study was obtained from Cancer Council Victoria’s Human Research Ethics Committee (IER 2002). All methods were carried out in accordance with the relevant guidelines and regulations laid down in the Declaration of Helsinki. All participants provided electronic informed consent at the sta... | PMC9969365 |
Consent for publication | Not applicable. | PMC9969365 | ||
Competing Interests | cancer | CANCER | Authors (MS, HD, EB and MW) are employed by a non-profit organisation that conducts research, public health interventions and advocacy aimed at reducing alcohol-related health harms in the community, especially pertaining to cancer. EB and SP sit on government and/or non-government organisation advisory committees over... | PMC9969365 |
List of abbreviations | National Rugby LeagueSocio-economic status | PMC9969365 | ||
References | PMC9969365 | |||
Subject terms | REFRACTORY MULTIPLE MYELOMA | Elranatamab is a humanized B-cell maturation antigen (BCMA)-CD3 bispecific antibody. In the ongoing phase 2 MagnetisMM-3 trial, patients with relapsed or refractory multiple myeloma received subcutaneous elranatamab once weekly after two step-up priming doses. After six cycles, persistent responders switched to biweekl... | PMC10504075 | |
Main | tumor necrosis | MULTIPLE MYELOMA, DISEASE PROGRESSION, TUMOR NECROSIS, MYELOMA, REFRACTORY MULTIPLE MYELOMA | The introduction of immunomodulatory drugs, proteasome inhibitors and anti-CD38 monoclonal antibodies has transformed the treatment landscape in multiple myeloma. The addition of these agents has substantially improved patient survival; however, outcomes for patients with disease progression after these agents remain p... | PMC10504075 |
Results | PMC10504075 | |||
Primary and secondary efficacy endpoints | After a median follow-up of 14.7 months (range: 0.2–25.1 months), the primary endpoint was met with 61.0% (95% confidence interval (CI): 51.8–69.6) of patients having a confirmed objective response per BICR. The best overall response is summarized in Fig. | PMC10504075 | ||
CRS profile of patients who received the 12/32-mg two-step-up priming regimen. | CRS | CRS experienced by each of the 119 patients who received the 12/32-mg two step-up priming regimen is shown by grade after each dose received. Grade 0 denotes no CRS.A total of 55 (44.7%) patients died while on study, the majority ( | PMC10504075 | |
Efficacy and safety with Q2W dosing | Among responders per BICR who switched to Q2W dosing at least 6 months before the data cutoff date ( | PMC10504075 | ||
Discussion | multiple myeloma, neutropenia, neuropathy, toxicity, toxicities, extramedullary disease, infections, CRS, TEAEs, anemia, penta-refractory disease | MULTIPLE MYELOMA, NEUTROPENIA, NEUROPATHY, DISEASE, EVENT, INFECTIONS, COMPLICATIONS, COMPLICATION, ANEMIA, EVENTS, REFRACTORY MULTIPLE MYELOMA | In this phase 2 study in patients with relapsed or refractory multiple myeloma, subcutaneous elranatamab at a dose of 76 mg weekly following a two step-up priming dose regimen of 12 mg and 32 mg during the first week of treatment induced early, deep and durable responses with a manageable safety profileA consistent ben... | PMC10504075 |
Methods | PMC10504075 | |||
Study design and patients | multiple myeloma, Guillain–Barré syndrome, squamous cell skin cancer or carcinoma, organomegaly, thromboembolic, malignancy, viral infection, impaired cardiovascular function, psychiatric, amyloidosis, skin changes syndrome, human immunodeficiency virus, prolonged QT syndrome, peripheral sensory or motor neuropathy, in... | CARDIOVASCULAR DISEASE, PLASMA CELL DISORDER, VIRAL INFECTION, AMYLOIDOSIS, EVENTS, REFRACTORY MULTIPLE MYELOMA, ACUTE MYOCARDIAL INFARCTION, INFECTIONS, POLYNEUROPATHY, SMOLDERING MULTIPLE MYELOMA, MULTIPLE MYELOMA, ENDOCRINOPATHY, GRAFT VERSUS HOST DISEASE, MOTOR NEUROPATHY, PLASMA CELL LEUKEMIA, HEPATITIS C, HYPERSE... | MagnetisMM-3 is an ongoing, multicenter, open-label, single-arm, phase 2 study to evaluate the efficacy and safety of elranatamab monotherapy in patients with relapsed or refractory multiple myeloma.Eligible patients were male or female (if not pregnant or breastfeeding), 18 years of age or older, willing to follow pro... | PMC10504075 |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.